Synovial Fibroblast 3.2: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis-diagnosed donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 2 of 2) - Dataset (ID:20235)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 4 | GRO-a | 209.0 | 34 | |
RA2159 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 4 | GRO-a | 10208.0 | 51 | |
N2645 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 4 | GRO-a | 76.5 | 44 | |
N2645 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 4 | GRO-a | 732.0 | 49 | |
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 4 | GRO-a | 2768.0 | 59 | |
RA2708 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 4 | GRO-a | 11651.0 | 41 | |
RA2159 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 4 | GRO-a | 15615.0 | 53 | |
RA2159 | Poly(I:C) | 2 | ug/mL | 4 | GRO-a | 17465.0 | 53 | ||||
N2645 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 4 | GRO-a | 8405.5 | 38 | |
N2645 | Poly(I:C) | 2 | ug/mL | 4 | GRO-a | 16181.5 | 44 | ||||
RA2708 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 4 | GRO-a | 18675.0 | 32 | |
RA2708 | Poly(I:C) | 2 | ug/mL | 4 | GRO-a | 16615.0 | 43 | ||||
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 4 | GRO-a | 460.0 | 51 | |
RA2159 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 4 | GRO-a | 16032.0 | 41 | |
N2645 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 4 | GRO-a | 844.0 | 36 | |
N2645 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 4 | GRO-a | 8773.0 | 53 | |
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 4 | GRO-a | 3426.0 | 51 | |
RA2708 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 4 | GRO-a | 18755.0 | 44 | |
RA2159 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 4 | GRO-a | 19999.0 | 70 | |
RA2159 | IL-1 alpha | 100 | ng/mL | 4 | GRO-a | 19748.0 | 59 | ||||
N2645 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 4 | GRO-a | 17762.0 | 44 | |
N2645 | IL-1 alpha | 100 | ng/mL | 4 | GRO-a | 18481.0 | 40 | ||||
RA2708 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 4 | GRO-a | 20638.0 | 37 | |
RA2708 | IL-1 alpha | 100 | ng/mL | 4 | GRO-a | 19577.0 | 42 | ||||
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 4 | GRO-a | 1016.5 | 42 |